找回密碼
 To register

QQ登錄

只需一步,快速開(kāi)始

掃一掃,訪問(wèn)微社區(qū)

打印 上一主題 下一主題

Titlebook: Development of Antibody-Based Therapeutics; Translational Consid Mohammad A. Tabrizi,Gadi G. Bornstein,Scott L. Kla Book 20121st edition Sp

[復(fù)制鏈接]
樓主: mobility
31#
發(fā)表于 2025-3-26 22:14:47 | 只看該作者
Biophysical Considerations for Development of Antibody-Based Therapeutics,–antigen complexes for drug candidate optimization and the design of clinical dosing strategies. For measuring the dissociation equilibrium constants of mAbs binding reversibly to antigens, two premier technologies are commonly used: Biacore surface plasmon resonance (SPR) and the solution-based kin
32#
發(fā)表于 2025-3-27 02:07:59 | 只看該作者
33#
發(fā)表于 2025-3-27 05:46:01 | 只看該作者
Bioanalytical Considerations for Development of Antibody-Based Therapeutics: Pharmacokinetics and Ifor successful translation of information into the later phases of antibody development require the use of relevant bioanalytical (BA) methodologies from early preclinical stages. Here, we discuss a suite of BA methodologies that can be used to enable pharmacokinetics, immunogenicity, and biomarker
34#
發(fā)表于 2025-3-27 10:56:23 | 只看該作者
35#
發(fā)表于 2025-3-27 16:09:16 | 只看該作者
36#
發(fā)表于 2025-3-27 19:24:59 | 只看該作者
37#
發(fā)表于 2025-3-28 00:17:34 | 只看該作者
Application of Pharmacokinetic/Pharmacodynamic Modeling in the Development of Antibody-Based Theraplved from a simple descriptive endeavor to an essential component of model-based drug development. The role of PK/PD modeling can be more critical for antibody-based therapeutics owing to their complex pharmacological properties. Nonlinear behavior can manifest in most of the physiological processes
38#
發(fā)表于 2025-3-28 03:26:02 | 只看該作者
Application of Population Pharmacokinetic-Pharmacodynamic Approaches in the Design of Translational few decades. The development of antibody-based therapeutics has benefited substantially from the utilization of population approaches. Moreover, almost all FDA-approved monoclonal antibody therapeutics have been evaluated using population approaches. In this chapter, application of population PK-PD
39#
發(fā)表于 2025-3-28 08:38:47 | 只看該作者
Translational Biomarkers: Essential Tools in Development of Antibody-Based Therapeutics,f relevant biomarkers can streamline this process significantly. Selecting and evaluating relevant biomarkers early on not only lessens the time and cost associated with clinical evaluation, but also fosters implementation of rational decision-making processes throughout various antibody development
40#
發(fā)表于 2025-3-28 11:51:10 | 只看該作者
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛(ài)論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評(píng) 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國(guó)際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-8 01:15
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
华宁县| 永吉县| 平凉市| 元朗区| 梁河县| 滨州市| 茌平县| 个旧市| 莱州市| 芜湖县| 金昌市| 如皋市| 青神县| 镶黄旗| 双牌县| 砚山县| 习水县| 抚宁县| 吉水县| 云浮市| 康乐县| 西丰县| 西和县| 太原市| 句容市| 常熟市| 古交市| 延安市| 永仁县| 吴忠市| 景东| 花莲市| 新乐市| 栾城县| 旬阳县| 宁陕县| 志丹县| 东兴市| 潼南县| 仁布县| 凤山县|